Study on the influential factors of blood concentration for duloxetine based on therapeutic drug monitoring

LUN Yang; DUAN Liguang; AN Feiyue; FU Ran; YU Jing; CHEN Chaoli; ZHAO Mengqiang; SU Shi; SONG Yang; WANG Jiaqi; YAN Yuhang; ZHOU Chunhua

doi:10.6039/j.issn.1001-0408.2025.06.15

您当前的位置：

首页 >

文章列表页 >

Study on the influential factors of blood concentration for duloxetine based on therapeutic drug monitoring

更新时间：2025-09-25

- Study on the influential factors of blood concentration for duloxetine based on therapeutic drug monitoring
- ZHONGGUO YAOFANG Vol. 36, Issue 6, Pages: 727-731(2025)
- 作者机构：
  
  1.河北医科大学第一医院临床药学部，石家庄　050023
  2.河北医科大学第一医院药学部，石家庄　050023
  3.河北省人工智能临床药学技术创新中心，石家庄　050031
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.06.15
  CLC： R969;R971+.43
- Received：13 October 2024，
  
  Revised：2025-02-12，
  
  Accepted：12 February 2025，
  
  Published：30 March 2025
- 稿件说明：
移动端阅览
伦杨,段立广,安绯悦,等.基于治疗药物监测的度洛西汀血药浓度影响因素研究[J].中国药房,2025,36(06):727-731.

LUN Yang,DUAN Liguang,AN Feiyue,et al.Study on the influential factors of blood concentration for duloxetine based on therapeutic drug monitoring[J].ZHONGGUO YAOFANG,2025,36(06):727-731.
伦杨,段立广,安绯悦,等.基于治疗药物监测的度洛西汀血药浓度影响因素研究[J].中国药房,2025,36(06):727-731. DOI： 10.6039/j.issn.1001-0408.2025.06.15.

LUN Yang,DUAN Liguang,AN Feiyue,et al.Study on the influential factors of blood concentration for duloxetine based on therapeutic drug monitoring[J].ZHONGGUO YAOFANG,2025,36(06):727-731. DOI： 10.6039/j.issn.1001-0408.2025.06.15.

摘要

目的

探讨度洛西汀血药浓度的主要影响因素，为度洛西汀的个体化用药提供科学依据。

方法

回顾性选择2022年1月至2024年4月河北医科大学第一医院使用度洛西汀治疗并进行血药浓度监测的434例抑郁障碍住院患者，分析其性别、年龄、体重指数（BMI）、基因表型、合并用药、药品类型（原研/仿制）、基因单核苷酸多态性位点分型结果等对血药浓度及剂量校正后血药浓度（

）的影响。

结果

度洛西汀血药浓度为76.65（45.57，130.31） ng/mL，

为[0.96（0.63，1.60）

]

ng·d/（mL·mg）。度洛西汀日剂量与血药浓度之间存在显著正相关关系（决定系数为0.253 7，

＜0.001）。38.94%的患者度洛西汀血药浓度超出指南建议范围。性别、年龄、BMI、合用CYP2D6酶抑制剂、

CYP2D6

和

CYP1A2

表型对度洛西汀的

有显著影响（

＜0.05）。

结论

患者的年龄、性别、BMI、合并用药、基因表型与度洛西汀的血药浓度密切相关。

Abstract

OBJECTIVE

To explore the main factors influencing the blood concentration of duloxetine， and provide a scientific basis for the individualized use of duloxetine.

METHODS

Retrospective analysis was conducted on 434 inpatients with depressive disorders at the First Hospital of Hebei Medical University， who were treated with duloxetine and underwent blood concentration monitoring between January 2022 and April 2024. The study examined the impact of various factors， including gender， age， body mass index （BMI）， gene phenotypes， combined medication， drug type （original/generic）， and genotyping results of gene single nucleotide polymorphism loci， on blood concentration and the concentration-to-dose （

） after dose adjustment.

RESULTS

The blood concentration of duloxetine was 76.65 （45.57， 130.31） ng/mL， and

was 0.96 （0.63， 1.60） ng·d/（mL·mg）. The blood concentration of duloxetine was positively correlated with the daily dose of administration （

＝0.253 7，

＜0.001）. Blood concentration of duloxetine in 38.94% of patients exceeded the recommended range specified in the guidelines. Gender， age， BMI， combined use of CYP2D6 enzyme inhibitors， and

CYP2D6

and

CYP1A2

phenotypes had significant effects on

of duloxetine （

＜0.05）.

CONCLUSIONS

The patient’s age， gender， BMI， combined medication， and genetic phenotypes are closely related to the blood concentration of duloxetine.

关键词

Keywords

references

GBD 2019 Diseases and Injuries Collaborators . Global burden of 369 diseases and injuries in 204 countries and territories，1990-2019：a systematic analysis for the Global Burden of Disease Study 2019 [J ] . Lancet ， 2020 ， 396 （ 10258 ）： 1204 - 1222 .

RODRIGUES-AMORIM D ， OLIVARES J M ， SPUCH C ， et al . A systematic review of efficacy，safety，and tolerability of duloxetine [J ] . Front Psychiatry ， 2020 ， 11 ： 554899 .

THASE M E ， PRITCHETT Y L ， OSSANNA M J ， et al . Efficacy of duloxetine and selective serotonin reuptake inhibitors：comparisons as assessed by remission rates in patients with major depressive disorder [J ] . J Clin Psychopharmacol ， 2007 ， 27 （ 6 ）： 672 - 676 .

LI Q S ， TIAN C ， HINDS D ， et al . Genome-wide association studies of antidepressant class response and treatment-resistant depression [J ] . Transl Psychiatry ， 2020 ， 10 （ 1 ）： 360 .

SKINNER M H ， KUAN H Y ， PAN A L ， et al . Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers [J ] . Clin Pharmacol Ther ， 2003 ， 73 （ 3 ）： 170 - 177 .

SI T M ， KNADLER M P ， LIM M T ， et al . Pharmacokine-tics and tolerability of duloxetine following oral admini-stration to healthy Chinese subjects [J ] . Clin Pharmacokinet ， 2007 ， 46 （ 9 ）： 767 - 775 .

CHAN C ， YEO K P ， PAN A X ， et al . Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects [J ] . Br J Clin Pharmacol ， 2007 ， 63 （ 3 ）： 310 - 314 .

American Psychiatric Association . Diagnostic and statistical manual of mental disorders [M ] . 5th edition . Arlington，VA ： American Psychiatric Publishing ， 2013 ： 5 - 18 .

中国药理学会治疗药物监测研究专业委员会，中国医师协会精神科医师分会，中国药理学会药源性疾病学委员会，等 . 中国精神科治疗药物监测临床应用专家共识：2022年版 [J ] . 神经疾病与精神卫生， 2022 ， 22 （ 8 ）： 601 - 608 .

The Professional Committee for Therapeutic Drug Monitoring Research of the Chinese Pharmacological Society ， the Psychiatric Branch of the Chinese Medical Doctor Association ， the Drug Induced Disease Committee of the Chinese Pharmacological Society ， et al . Expert consensus on clinical application of psychiatric therapeutic drug monitoring in China：2022 edition [J ] . J Neurosci Ment Health ， 2022 ， 22 （ 8 ）： 601 - 608 .

HOLE K ， GANGSØ S ， JENSSTUEN Å T ， et al . Effect of CYP2D6 genotype on duloxetine serum concentration [J ] . Basic Clin Pharmacol Toxicol ， 2024 ， 134 （ 1 ）： 186 - 192 .

SONG Y ， CHANG L Y ， LUN Y ， et al . Analysis of factors affecting concentrations and concentration-to-dose ratios of trazodone [J ] . Ther Drug Monit ， 2024 ， 46 （ 2 ）： 252 - 258 .

HERTZ D L ， SNAVELY A C ， MCLEOD H L ， et al . In vivo assessment of the metabolic activity of CYP2D6 dip-lotypes and alleles [J ] . Br J Clin Pharmacol ， 2015 ， 80 （ 5 ）： 1122 - 1130 .

PharmGKB . Gene-specific information tables for CYP 2 D 6 [EB/OL ] .[ 2024-11-28 ] . https：//www.pharmgkb.org/page/cyp2d6RefMaterials https://www.pharmgkb.org/page/cyp2d6RefMaterials .

HIEMKE C ， BERGEMANN N ， CLEMENT H W ， et al . Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology：update 2017 [J ] . Pharmacopsychiatry ， 2018 ， 51 （ 1/2 ）： 9 - 62 .

谯明，朱毅，靳路，等 . 度洛西汀在抑郁症患者中血药浓度/剂量比的影响因素研究 [J ] . 中国医院用药评价与分析， 2024 ， 24 （ 6 ）： 672 - 675 .

QIAO M ， ZHU Y ， JIN L ， et al . Influencing factors of duloxetine on blood concentration/dose ratio in patients with depression [J ] . Eval Anal Drug Use Hosp China ， 2024 ， 24 （ 6 ）： 672 - 675 .

KNADLER M P ， LOBO E ， CHAPELL J ， et al . Dulo-xetine：clinical pharmacokinetics and drug interactions [J ] . Clin Pharmacokinet ， 2011 ， 50 （ 5 ）： 281 - 294 .

HICKS J K ， BISHOP J R ， SANGKUHL K ， et al . Clinical Pharmacogenetics Implementation Consortium（CPIC）guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors [J ] . Clin Phar-macol Ther ， 2015 ， 98 （ 2 ）： 127 - 134 .

RELLING M V ， KLEIN T E . CPIC：Clinical Pharmacogenetics Implementation Consortium of the pharmacogeno-mics research network [J ] . Clin Pharmacol Ther ， 2011 ， 89 （ 3 ）： 464 - 467 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Application and prospect of artificial intelligence and population pharmacokinetics in personalized medication after organ transplantation

Blood concentration monitoring of tacrolimus in patients with nephrotic syndrome and establishment of MLP prediction model

Study on the correlation between opioid-induced constipation and gene polymorphism

Application of machine learning in the therapeutic drug monitoring and individual drug therapy

Study on the Relationship between Adverse Reaction of Opioid Constipation and Gene Polymorphism

Related Author

LI Yan

ZHU Yanjiao

WU Xichao

GAO Rui

ZHOU Penglin

LI An’an

ZONG Huiying

HE Shuai

Related Institution

School of Pharmacy， Shandong University of Traditional Chinese Medicine

Clinical Pharmacy Affairs of the First Affiliated Hospital of Shandong First Medical University （Shandong Qianfoshan Hospital） /Shandong Engineering and Technology Research Center for Pediatric Drug Clinical Evaluation and R&D/Shandong Provincial Key Laboratory of Clinical Pharmacy in Medicine and Health， Jinan 250014， China］

School of Pharmacy， Fujian Medical University

Dept. of Pharmacy， Zhongshan Hospital Affiliated to Xiamen University

Xiamen Pharmaceutical Association

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰